S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Forecast, Price & News

$1.42
+1.00 (+238.10%)
(As of 07/31/2023)
Compare
Today's Range
$1.35
▼
$1.90
50-Day Range
$0.41
▼
$1.62
52-Week Range
$1.22
▼
$8.45
Volume
717,200 shs
Average Volume
29,344 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

NBRV Price History

NBRV Stock News Headlines

September 30, 2023 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Stock Passes Below Fifty Day Moving Average of $0.78
September 30, 2023 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 25, 2023 | americanbankingnews.com
Reviewing Nabriva Therapeutics (NASDAQ:NBRV) & Mereo BioPharma Group (NASDAQ:MREO)
September 22, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
July 11, 2023 | finanznachrichten.de
Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives
May 26, 2023 | finance.yahoo.com
NBRV - Nabriva Therapeutics plc
February 28, 2023 | marketwatch.com
Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
February 25, 2023 | seekingalpha.com
NBRV Nabriva Therapeutics plc
January 6, 2023 | finance.yahoo.com
Nabriva Therapeutics Provides Corporate Update
November 28, 2022 | marketwatch.com
Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data
November 28, 2022 | markets.businessinsider.com
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
November 28, 2022 | markets.businessinsider.com
Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up
November 28, 2022 | bizjournals.com
Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment
November 28, 2022 | seekingalpha.com
Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate
November 28, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
November 28, 2022 | finance.yahoo.com
Nabriva's stock is up after sharing antibiotic news
November 28, 2022 | finance.yahoo.com
Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment
November 10, 2022 | finance.yahoo.com
Montgomery County biopharmaceutical firm reducing workforce by 40%
November 10, 2022 | technews.tmcnet.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 | finance.yahoo.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 7, 2022 | finance.yahoo.com
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
September 15, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
September 14, 2022 | finance.yahoo.com
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
September 6, 2022 | finance.yahoo.com
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 12, 2022 | marketwatch.com
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Company Calendar

Last Earnings
5/06/2021
Today
10/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
CUSIP
N/A
CIK
1641640
Web
www.nabriva.com
Phone
(531) 649-2000
Fax
610-816-6639
Employees
39
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($19.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%
Return on Equity
-365.53%
Return on Assets
-135.81%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.85
Quick Ratio
0.52

Sales & Book Value

Annual Sales
$35.59 million
Price / Sales
1.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
14.20

Miscellaneous

Outstanding Shares
32,015,000
Free Float
31,493,000
Market Cap
$45.46 million
Optionable
Optionable
Beta
1.53
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Colin Broom M.D. (Age 67)
    Director
    Comp: $40k
  • Mr. J. Christopher Naftzger BAMr. J. Christopher Naftzger BA (Age 56)
    Esq., J.D., Interim CEO, Gen. Counsel & Sec.
  • Mr. Daniel Dolan (Age 46)
    Chief Financial Officer

Key Competitors

View All Competitors













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings or view top-rated stocks.

How have NBRV shares performed in 2023?

Nabriva Therapeutics' stock was trading at $1.89 at the start of the year. Since then, NBRV stock has decreased by 24.9% and is now trading at $1.42.
View the best growth stocks for 2023 here.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share for the quarter, beating analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analyst estimates of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%.
Read the conference call transcript.

When did Nabriva Therapeutics' stock split?

Nabriva Therapeutics shares reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.42.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $45.46 million and generates $35.59 million in revenue each year. The biotechnology company earns $-57,190,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -